Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia

Clinical Pharmacokinetics

Volumn 47, Issue 12, 2008, Pages 793-805

  Garazzino, Silvia ^a,c   Aprato, Alessandro ^b   Baietto, Lorena ^a   D'Avolio, Antonio ^a   Maiello, Agostino ^a   De Rosa, Francesco Giuseppe ^a   Aloj, Domenico ^b   Siccardi, Marco ^a   Biasibetti, Antonio ^b   Massè, Alessandro ^b   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Traumatologic and Orthopaedic Hospital   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

Author keywords

Bone; Glycopeptides, pharmacokinetics; Infectious arthritis; Teicoplanin, pharmacokinetics; Vancomycin, pharmacokinetics

Indexed keywords

C REACTIVE PROTEIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOCINA; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BONE INFECTION; CANCELLOUS BONE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICAL BONE; DEBRIDEMENT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; FEMALE; FRACTURE; FRACTURE EXTERNAL FIXATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDARTHROSIS; TIBIA; TISSUE DISTRIBUTION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CELL CULTURE TECHNIQUES; DEBRIDEMENT; ENTEROCOCCUS FAECALIS; FEMALE; GLYCOPEPTIDES; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDARTHROSIS; STAPHYLOCOCCUS EPIDERMIDIS; TEICOPLANIN; TIBIA; VANCOMYCIN; YOUNG ADULT;

EID: 56749184322     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200847120-00004     Document Type: Article

References (36)

1. Norden CW. Osteomyelitis. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990: 922-30
2. Cierny G, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Contemp Orthop 1985; 10: 17-37
3. Lieberman JR, Callaway GH, Salvati EA, et al. Treatment of the infected total hip arthroplasty with a two stage reimplantation protocol. Clin Orthopaed Related Res 1994; 301: 205-12
4. Redington J, Ebert SC, Craig WA. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Rev Infect Dis 1991; 13 Suppl. 10: 790-9
5. Tsukayama DT, Guay DRR, Peterson PK. Antibiotic therapy of chronic osteomyelitis. In: Gustilo RB, Gruninger RP, Tsukayama DT, editors. Orthopaedic infection: diagnosis and treatment. Philadelphia (PA): Saunders, 1989: 166-74
6. Darley ESR, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53: 928-35
7. Djabarouti S, Boselli E, Allaouchiche B, et al. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method. J Chromatogr B 2004; 799: 165-72
8. Roncoroni AJ, Manuel C, Nedjar C, et al. Cefamandole bone diffusion in patients undergoing total hip replacement. Chemotherapy 1981; 27 (3): 166-72
9. Cristofolini L, Viceconti M, Cappello A, et al. Mechanical validation of whole bone composite femur models. J Biomechanics 1996; 29: 525-35
10. Martin C, Alaya M, Mallet MN, et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994; 38 (2): 396-9
11. Vuorisalo S, Pokela R, Satta J, et al. Internal mammary artery harvesting and antibiotic concentrations in sternal bone during coronary artery bypass. Int J Angiol 2000; 9 (2): 78-81
12. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 2000; 22 (6): 661-7
13. Borner K, Hahn F, Koeppe P. Concentrations of vancomycin in human bone. J Chemother 1989; 1 (4 Suppl.): 588-9
14. Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin in infected and non-infected human bone. Antimicrob Agents Chemother 1988; 32: 1320-2
15. Massias L, Dubois C, De Lentdecker P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992; 36: 2539-41
16. Desplaces N, Mamoudy P, Ducroquet F, et al. Vancomycine en perfusion continue et infections ostéo-articulaires à staphylocoques multirésistants. Med Mal Innfect 1997; 27: 969-74
17. Garcia-Zabarte A, Penalver D, Aguilera A, et al. Serum and bone levels of teicoplanin in total hip replacement [abstract no. 0445]. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando (FL)
18. Rosina R, Avai A, Suter F, et al. Pharmacokinetics of teicoplanin in human bone [abstract no. 249]. 16th International Congress of Chemotherapy; 1989 Jun 18-20; Jerusalem
19. Sirot J, Dumont C, Delisle JJ, et al. Pénétration de la teicoplanine dans l'os [abstract no. 221]. Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse; 1986; Paris
20. Wilson AP, Taylor B, Treasure T, et al. Antibiotic prophylaxis in cardiac surgery: serum and tissue levels of teicoplanin, flucloxacillin and tobramycin. J Antimicrob Chemother 1988; 21 (2): 201-12
21. Martin C, Bourget P, Alaya M, et al. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997; 41 (5): 1150-5
22. De Lalla F, Novelli A, Pellizzer G, et al. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993; 37 (12): 2693-8
23. Lazzarini L, Novelli A, Marzano N, et al. Regional and systemic prophylaxis with teicoplanin in total knee arthroplasty. J Arthroplasty 2003; 18: 342-6
24. Nehrer S, Thalhammer F, Schwameis E, et al. Teicoplanin in the prevention of infection in total hip replacement. Arch Orthop Trauma Surg 1998; 118: 32-6
25. Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235-7
26. Boselli E, Allaouchiche B. Diffusion osseuse des antibiotiques. Presse Med 1999; 28: 2265-76
27. Goldstein FW, Mainardi JL. Sensibilité et résistance des souches: quotients inhibiteurs. In: Mainardi JL, editor. Prećis d'antibiothérapie pratique. Paris: Phase 5 Éditions Médicales, 1995: 81-147
28. Larsson AJ, Walker KJ, Raddaz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996; 38: 589-97
29. Ahmed A, Jafri H, Lutsar I, et al. Pharmacodynamics of vancomycin for the treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1999; 43: 876-81
30. Peetermans WE, Hoogeterp JJ, Hazekamp-van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in experimental infection. Antimicrob Agents Chemother 1990; 34: 1869-74
31. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86
32. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28 (2): 143-60
33. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of Invancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42
34. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997; 9 Suppl. 1: S64-73
35. MacGowan A, White L, Reeves D, et al. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1996; 2: 197-208
36. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs intermittent infusion. J Clin Pharm Therap 2004; 29: 351-7